Switching to integrase strand transfer inhibitors (INSTI) from protease inhibitors is associated with new diabetes risk in people with HIV.

Switching to INSTI-based ART from protease inhibitors is associated with an increased risk for incident diabetes in treatment-experienced adults.

The researchers found that weight gain did not explain effect of switching from protease inhibitors to INSTIs on diabetes risk. HealthDay News — Switching to integrase strand transfer inhibitors ...

During the first 2 years after switching from protease inhibitors to INSTIs, diabetes risk was higher, but not thereafter. HealthDay News — Switching to integrase strand transfer inhibitors (INSTI) ...

Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to the National Institutes of Health. Antiretroviral therapies that treat HIV ...

Merck’s Idvynso, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir gets US FDA approval for the treatment of HIV-1 infection: Rahway, New Jersey ...

This approval marks an important new chapter in Merck’s long-standing commitment to research and discovery for people living ...

Primary outcome measures The primary outcome was time to HIV care attrition, defined as death, discontinuation of ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the affected trials. After discussions with the FDA, Gilead has “discontinued ...

Ricardo Jiménez feels like he’s going crazy. The leader of public health initiatives at Chicago’s Puerto Rican Cultural Center is desperately trying to find a way to keep his HIV prevention programs ...